Metabolic Diseases: Clinical Trials

37,885 trials for Metabolic Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

23604 completed, 4855 unknown, 3359 recruiting, 1930 terminated. 14501 Not applicable, 4627 Phase 2, 4064 Phase 3, 3651 Phase 1, 3267 Phase 4.

By phase and status

PhaseTrialsStatus
Not applicable14501Completed 8975, Unknown 1989, Recruiting 1361, Not yet recruiting 640, Terminated 522, Active not recruiting 518, Withdrawn 318, Enrolling by invitation 130, Suspended 48
Phase 24627Completed 2941, Terminated 419, Unknown 383, Recruiting 326, Withdrawn 193, Active not recruiting 186, Not yet recruiting 137, Enrolling by invitation 28, Suspended 14
Phase 34064Completed 2906, Terminated 344, Unknown 290, Recruiting 201, Active not recruiting 118, Withdrawn 108, Not yet recruiting 74, Enrolling by invitation 16, Suspended 7
Phase 13651Completed 2631, Terminated 240, Unknown 236, Recruiting 225, Active not recruiting 108, Withdrawn 94, Not yet recruiting 92, Enrolling by invitation 13, Suspended 12
Phase 43267Completed 2099, Unknown 509, Terminated 230, Recruiting 169, Withdrawn 116, Not yet recruiting 73, Active not recruiting 53, Enrolling by invitation 14, Suspended 4
Early Phase 1363Completed 200, Recruiting 51, Unknown 39, Not yet recruiting 26, Active not recruiting 15, Terminated 14, Withdrawn 12, Enrolling by invitation 4, Suspended 2

Follow Metabolic Diseases: new trials by email Literature Review of Metabolic Diseases trials Research Report on Metabolic Diseases

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Inhibiting GABA Transaminase to Relieve Obesity Induced Hyperinsulinemia and Insulin Resistance
Vigabatrin Pill, Placebo oral tablet - Hyperinsulinism, Insulin Resistance
Phase 2WithdrawnUniversity of Arizona2030-04-152025-07-30
MEDBRIDGE-Guided NCM/CHW Post-Discharge Support for High-Risk T2D Patients
MEDBRIDGE-Guided NCM/CHW Post-Discharge Support Intervention - Type 2 Diabetes, Medication Adherence
Not applicableNot yet recruitingUniversity of Alabama at Birmingham452029-05-012026-05-20
A Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of TBN
Tetramethylpyrazine nitrone (TBN) tablet / Placebo - Healthy
Phase 1Not yet recruitingGuangzhou Magpie Pharmaceuticals Co., Ltd.162028-09-012026-09-11
Patient-engaged Development and Testing of Educational Content on Side Effects of Statins
Educational content on statin side effects - Dyslipidemia
Not applicableSuspendedWeill Medical College of Cornell University302028-09-012026-09-23
Insul-In This Together: Leveraging Family Support and Diabetes Technology for Adolescents Living With Type 1 Diabetes
Insul-In This Together - Diabetes Type 1
Not applicableNot yet recruitingStanford University2002028-01-012026-10-05
Prenatal Transplantation for Fetuses With Fanconi Anemia
IUHSCT for FA-affected fetuses - Fanconi Anemia, Anemia, Hypoplastic, Congenital
Phase 1 / Phase 2Not yet recruitingAgnieszka Czechowicz122028-01-012026-06-16
To Evaluate the Safety and Efficacy of GS1168 Injection in Adult Phenylketonuria
GS1168 injection - Phenylketonuria (PKU)
Early Phase 1Not yet recruitingGritgen Therapeutics Co., Ltd.92027-12-312026-09-10
The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction
Caloric Restriction, Hyperglycemic clamp - Type2diabetes
Phase 2Not yet recruitingAdrian Vella202027-12-152026-10-28
Efficacy, Safety, and Treatment Satisfaction of Once-Weekly Tirzepatide in Obese Type 2 Diabetic Patients
Tirzepatide + Standard Therapy (Intervention Group), Standard Oral Antidiabetic Drugs (OADs) - Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Not applicableNot yet recruitingAkhtar Saeed Medical and Dental College522027-12-122026-10-29
PAtient Similarity for Decision-Making in Prevention of Cardiovascular Toxicity (PACT): A Feasibility Study
Clinical Decision Aid, Standard Care - Heart Failure, Coronary Artery Disease
Not yet recruitingMedical College of Wisconsin602027-12-012026-11-03
Liver Steatosis in Pediatric CD Patients
Gluten-free diet - Celiac Disease in Children, Non-Alcoholic Fatty Liver Disease
RecruitingUniversity of Palermo912027-11-012026-05-01
Role of Endothelial Dysfunction on Exercise Pressor Reflex in Type 2 Diabetes
MitoQ (mitoquinol mesylate), Placebo - Type 2 Diabetes (T2DM), Endothelial Dysfunction
Not applicableNot yet recruitingMedical College of Wisconsin402027-10-012026-10-30
Implementation Support for HEARTS-Based Hypertension and Diabetes Care in Guatemala
HEARTS implementation support, Routine HEARTS implementation - Hypertension (HTN), Type 2 Diabetes
Not applicableNot yet recruitingUniversity of Michigan14402027-10-012026-11-12
Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes Mellitus
Semaglutide (Wegovy) weekly injection - Gestational Diabetes Mellitus (GDM), Metabolic Syndrome
Phase 2 / Phase 3Not yet recruitingUniversity of Massachusetts, Worcester2262027-09-012026-09-28
GLP-1 RA for Stage 1 Type 1 Diabetes
Semaglutide, Placebo - Stage 1 Diabetes Mellitus, Type 1
Phase 2Not yet recruitingChildren's Hospital Medical Center, Cincinnati152027-09-012026-02-24
Evaluation of Donor-Derived B Cell Infusions in Patients With Amyotrophic Lateral Sclerosis (ALS)
B cell infusion - ALS - Amyotrophic Lateral Sclerosis
Phase 1Not yet recruitingMark Poznansky102027-09-012026-09-24
Anti-Interleukin-6 (IL6) in Calciphylaxis
Tocilizumab - Calciphylaxis
Phase 1Not yet recruitingBoston Medical Center102027-09-012026-07-16
South Asians With Type 2 Diabetes at Risk for Depression
CHW-led T2D Intervention - Type 2 Diabetes
Not applicableNot yet recruitingNYU Langone Health1002027-08-012026-05-19
Community Health Worker Nutrition Self-Management Support for Cardio-Kidney-Metabolic Health
INTEGRATE-CHW, Usual Care - Hypertension (HTN), CKD - Chronic Kidney Disease
Not applicableNot yet recruitingFlorida International University2002027-07-152026-11-05
cfMSC Therapy for Diabetes
cfMSC therapy for diabetes - Type II Diabetes Mellitus
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute302027-06-302026-11-02

Showing 20 of 37885. Sign in to see all of them.

Narrower conditions

Diabetes Mellitus, Type 2 (10061)  ·  Diabetes Mellitus (8230)  ·  Diabetes Mellitus, Type 1 (3573)  ·  Obesity (3052)  ·  Insulin Resistance (2966)  ·  Metabolic Syndrome (2098)  ·  Osteoporosis (1557)  ·  Hypertension (1545)  ·  Cardiovascular Diseases (1230)  ·  Dyslipidemias (1202)  ·  Hypercholesterolemia (1135)  ·  Motor Activity (1054)  ·  Amyotrophic Lateral Sclerosis (978)  ·  Prediabetic State (917)  ·  Overweight (868)

Broader conditions

Nutritional and Metabolic Diseases (37845)  ·  Glucose Metabolism Disorders (24042)  ·  Endocrine System Diseases (20937)  ·  Diabetes Mellitus (12065)  ·  Pathological Conditions, Signs and Symptoms (8359)  ·  Signs and Symptoms (5199)  ·  Nervous System Diseases (4987)  ·  Hyperinsulinism (4719)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4692)  ·  Immune System Diseases (4671)  ·  Genetic Diseases, Inborn (4328)  ·  Lipid Metabolism Disorders (4186)  ·  Cardiovascular Diseases (4069)  ·  Nutrition Disorders (3902)

Interventions

Metformin (1051)  ·  Exercise (589)  ·  Insulin Glargine (542)  ·  Insulin (458)  ·  Sitagliptin Phosphate (404)  ·  Atorvastatin (331)  ·  Insulin Aspart (328)  ·  dapagliflozin (314)  ·  semaglutide (309)  ·  Pioglitazone (301)  ·  Liraglutide (280)  ·  empagliflozin (270)  ·  Sodium Chloride (237)  ·  Blood Specimen Collection (234)  ·  Standard of Care (233)

Sponsors

Novo Nordisk A/S (860)  ·  AstraZeneca (545)  ·  Eli Lilly and Company (386)  ·  Sanofi (374)  ·  Merck Sharp & Dohme LLC (277)  ·  Assistance Publique - Hôpitaux de Paris (218)  ·  Mayo Clinic (218)  ·  Novartis Pharmaceuticals (217)  ·  Massachusetts General Hospital (212)  ·  GlaxoSmithKline (206)  ·  University of Aarhus (205)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (195)  ·  Takeda (188)  ·  Pfizer (182)  ·  University of Colorado, Denver (173)

Countries

United States (13365)  ·  Canada (2605)  ·  Germany (2298)  ·  United Kingdom (2293)  ·  China (2270)  ·  France (2219)  ·  Italy (1844)  ·  Spain (1581)  ·  Denmark (1485)  ·  Netherlands (1218)  ·  South Korea (1204)  ·  Turkey (Türkiye) (1064)  ·  Poland (901)  ·  Australia (896)  ·  Brazil (896)

Results publications

PMID 38770818, PMID 40576086, PMID 39963952, PMID 33166419, PMID 22236356, PMID 25387217, PMID 38682786, PMID 25504028, PMID 35472672, PMID 31903692, PMID 32998732, PMID 32501595, PMID 37526194, PMID 30183102, PMID 33078867, PMID 35044568, PMID 37994400, PMID 38979716, PMID 39171639, PMID 21518985, PMID 22913891, PMID 24275240, PMID 31606880, PMID 32588430, PMID 32803882, PMID 34213819, PMID 22825366, PMID 23010561, PMID 26894924, PMID 33512717, PMID 32267058, PMID 33210751, PMID 37467180, PMID 38018702, PMID 39735417, PMID 24533607, PMID 25430806, PMID 26580237, PMID 27402391, PMID 27777279, PMID 33107592, PMID 34298554, PMID 36542287, PMID 37435938, PMID 24517339, PMID 32306296, PMID 33327727, PMID 38837240, PMID 21450987, PMID 21883806

NIH funding

2015 (124), 2023 (115), 2017 (105), 2019 (105), 2009 (100), 2025 (99), 2014 (98), 2018 (95), 2016 (90), 2008 (86), 2005 (55), U54NS065768 (19), 2004 (14), OT2HL158287 (11), P30CA015704 (10)